Clinical development and regulatory services for biotech drug programs
Allucent operates a consulting and clinical operations business serving biotech companies through drug development, regulatory affairs, and clinical trial execution. The tech stack reveals a heavy investment in statistical programming (SAS, R, NONMEM, Phoenix WinNonlin) and clinical data standards (CDISC), paired with modern integration platforms (MuleSoft, Boomi, IBM Integration Bus) — signaling infrastructure built to bridge legacy clinical systems with contemporary data pipelines. Active hiring skews heavily senior (23 of 36 roles at director+ level), indicating a services firm scaling expertise-driven teams rather than entry-level capacity.
Notable leadership hires: Therapeutic Strategy Head, Director CMC
Allucent is a global provider of drug development solutions, including clinical operations, biostatistics, regulatory affairs, and clinical pharmacology services. The company serves small and mid-sized biotech firms navigating early-stage and mid-stage development programs across therapeutic areas including oncology, rare diseases, and cell & gene therapy. With operations across 60+ countries and 1,001–5,000 employees, Allucent delivers consulting-led partnerships focused on regulatory strategy, trial design, and clinical data management. Active projects center on decentralized trial models, pre-approval development planning, and real-world data integration—reflecting industry-wide shifts toward remote trial execution and post-market evidence generation.
SAS, R, and NONMEM for statistical analysis; Phoenix WinNonlin for pharmacokinetics; CDISC for clinical data standards; AWS for cloud infrastructure; MuleSoft and Dell Boomi for integration; Tableau and Power BI for reporting; React, Spring Boot, and Node.js for application development.
Cary, North Carolina, United States. The company operates globally across 60+ countries with 1,001–5,000 employees.
Other companies in the same industry, closest in size